financetom
Business
financetom
/
Business
/
James Hardie Industries Fiscal Q2 Adjusted EPS Decreases, Revenue Rises; Names New CFO; Shares Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
James Hardie Industries Fiscal Q2 Adjusted EPS Decreases, Revenue Rises; Names New CFO; Shares Rise After Hours
Nov 17, 2025 2:35 PM

05:05 PM EST, 11/17/2025 (MT Newswires) -- James Hardie Industries ( JHIUF ) reported fiscal Q2 adjusted earnings Monday of $0.26 per diluted share, down from $0.36 a year earlier.

Analysts polled by FactSet expected $0.26.

Revenue for the quarter ended Sept. 30 was $1.29 billion, up from $960.8 million a year earlier.

Analysts surveyed by FactSet expected $1.28 billion.

Separately, the company said Monday it named Ryan Lada as chief financial officer, effective immediately.

Lada succeeds Rachel Wilson, who has decided to step down after two years in her position, the company said, adding Wilson will stay in an advisory role until March 31.

Lada was most recently CFO at Watts Water Technologies, James Hardie said.

James Hardie also said Monday it named Nigel Stein as chair of its board.

Stein was previously chair of Inchcape, the company said.

James Hardie shares were rising 13% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder
US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder
Mar 21, 2024
By Mariam Sunny and Sruthi Narasimha Chari March 21 (Reuters) - The U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder, the health regulator said on Thursday. The oral drug, to be sold under the brand name Duvyzat, is the first nonsteroidal drug approved to treat patients with all genetic...
CERAWEEK-Exxon ahead of schedule on doubling LNG portfolio, exec says
CERAWEEK-Exxon ahead of schedule on doubling LNG portfolio, exec says
Mar 21, 2024
HOUSTON, March 21 (Reuters) - Exxon Mobil ( XOM ) is ahead of schedule with its plan to double the size of its liquefied natural gas (LNG) portfolio to 40 million tons per annum (mtpa) by 2030 and will focus on selling its own gas rather than trading that of third parties, the company's LNG chief said on Thursday. Exxon...
Boeing chair to meet key airline customers without planemaker's CEO, sources say
Boeing chair to meet key airline customers without planemaker's CEO, sources say
Mar 21, 2024
WASHINGTON, March 21 (Reuters) - Major airline chiefs plan to hold discussions with Boeing ( BA ) board chair Larry Kellner in meetings that will not include CEO David Calhoun after raising concerns over an Alaska Airlines mid-air emergency and ongoing production issues, sources said. A group of U.S. airline CEOs sought meetings with Boeing ( BA ) directors to...
Meta's Instagram down for thousands, Downdetector shows
Meta's Instagram down for thousands, Downdetector shows
Mar 21, 2024
March 21 (Reuters) - Meta Platforms's ( META ) Instagram was down for thousands of users on Thursday, according to outage tracking website Downdetector.com. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved